New clinical trial aims to prevent relapse in patients with DLBCL

(BPT) - For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that one in three will see their cancer return — typically within a year following completion of their initial treatment.[1] Today, the current standard of care following initial chemotherapy is to "watch and wait," an approach that monitors the patient for signs of relapse.

But what if there were a way to identify patients at risk of relapse earlier and treat them before the cancer has a chance to come back? That's the goal of the ALPHA3 clinical trial, a groundbreaking study investigating whether early intervention with an investigational CAR T cell product (cemacabtagene ansegedleucel or cema-cel, pronounced "SEM-a-sell") can help prevent relapse in DLBCL patients. CAR T therapy is a revolutionary approach to treating cancer that has shown promising results and high remission rates, particularly when used in blood cancers[2].

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Post a comment
Stop watching this discussion.